Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies.
The effects of an antisense phosphodiester oligodeoxynucleotide (ODN) directed to the NR1 subunit of the NMDA receptor mRNA and of its corresponding sense ODN were investigated in mice. Treatment with the antisense ODN significantly increased the time mice spent in the open arms of an elevated maze while the total number of arm entries was unaltered. Furthermore, seizure latencies after the administration of an ED100 dose of NMDA (150 mg/kg) were significantly higher in antisense treated animals compared to vehicle controls. At the same time, treatment with NR1 antisense ODN significantly reduced the Bmax of [3H]CGS-19755 binding (2101 fmol/mg protein) compared to both vehicle (2787 fmol/mg protein) and sense (2832 +/- 39 fmol/mg protein) controls without any significant change in KD (33 nM). A corresponding reduction of [3H]CGP-39653 binding was also observed after treatment with NR1 antisense compared to both sense and vehicle controls. In contrast, neither antisense nor sense ODNs altered the proportion of high affinity glycine sites or the potency of glycine at either high or low affinity glycine binding sites to inhibit [3H]CGP-39653 binding. These results show that in vivo treatment with NR1 antisense ODNs to the NMDA receptor complex reduces antagonist binding at NMDA receptors and has pharmacological effects similar to those observed with some NMDA receptor antagonists. These results also suggest that treatment with antisense ODNs may provide another means to investigate allosteric modulation of receptor subtypes in vivo.
Zapata
A
A
Departament de Bioanalítica Mèdica, CSIC, Barcelona, Catalonia, Spain.
Capdevila
J L
JL
Tarrason
G
G
Adan
J
J
Martínez
J M
JM
Piulats
J
J
Trullas
R
R
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*; D010875:Pipecolic Acids / Q000378:metabolism; D011869:Radioligand Assay; D018009:Receptors, Glycine / Q000187:drug effects / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics* / Q000378:metabolism; D012640:Seizures / Q000503:physiopathology
D014151:Anti-Anxiety Agents; D018691:Excitatory Amino Acid Antagonists; D016376:Oligonucleotides, Antisense; D010875:Pipecolic Acids; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C069052:CGP 39653; C053672:selfotel; D015763:2-Amino-5-phosphonovalerate